Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial-Reference-Cited by-同舟云学术

Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial

Published:2022-03 Issue:3 Volume:42 Page:253-262
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Takumoto Yuki^ORCID,Shiroiwa Takeru,Shimozuma Kojiro,Iwata Hiroji,Takahashi Masato,Baba Shinichi,Kobayashi Kokoro,Hagiwara Yasuhiro,Kawahara Takuya,Uemura Yukari,Mukai Hirofumi,Taira Naruto,Sawaki Masataka

Funder

Comprehensive Support Project for Oncology Research (CSPOR) of the Public Health Research Foundation, Japan

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40261-022-01124-y.pdf

Reference39 articles.

1. National Cancer Registry in Japan (2016–2018). Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare). https://ganjoho.jp/reg_stat/statistics/data/dl/excel/cancer_incidenceNCR(2016-2018).xlsof subordinate document. Accessed 29 July 2021.

2. Iwata H, Saji S, Ikeda M, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines, 2018 edition: the tool for shared decision making between doctor and patient. Breast Cancer. 2020;27(1):1–3. https://doi.org/10.1007/s12282-019-01021-x(Epub 2019 Nov 22. Erratum in: Breast Cancer. 2021;28(4):987).

3. Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(4):452–78.

4. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29–36.

5. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366–73.